ArticleMedicine2026
Revealing causal associations of 91 inflammatory protein factors with endocarditis: Insights from genome-wide association study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory protein factors play key roles in the pathophysiology of endocarditis. Using publicly available population-level databases, this study investigates their potential causal relationships with endocarditis to identify candidate biomarkers for precise diagnosis and therapy. We performed 2-sample Mendelian randomization to investigate causal relationships between endocarditis and 91 circulating inflammatory proteins. Summary genome-wide association studies data for endocarditis were derived from the UK Biobank, and genome-wide association studies data for 91 inflammatory proteins were from European-ancestry cohorts. Single-nucleotide polymorphisms were used as instrumental variables. The inverse variance weighted method was the primary analytic approach; weighted median, MR-Egger, and Bayesian-weighted methods were applied as complementary approaches to validate causal effects. MR-Steiger was used to evaluate directionality. Inverse variance weighted results indicated that CD40L receptor levels were a potential risk factor for endocarditis (OR = 1.258, 95% confidence interval: 1.040-1.522, P = .018), whereas fibroblast growth factor 21 levels were protective (OR = 0.689, 95% confidence interval: 0.494-0.962, P = .029). Sensitivity analyses showed no significant heterogeneity by Cochran's Q test, and neither MR-Egger intercept nor MR-PRESSO global tests indicated horizontal pleiotropy (P > .05). Bayesian-weighted analysis further supported the causal relationships. We identified significant causal relationships between CD40L receptor levels, fibroblast growth factor 21 levels, and endocarditis, suggesting they may serve as potential biomarkers for endocarditis and offer directions for targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.